Weight loss (WL) is a frequent yet under-recognized complication of levodopa/carbidopa intestinal gel (LCIG) infusion, as well as a milestone of Parkinson disease (PD) disability progression. The complex association between weight loss, poor nutritional status, motor complications, and PD progression, however, remains unclear.
Levodopa-carbidopa intestinal gel infusion and weight loss in Parkinson's disease
Zibetti M;BECCARIA, LAURA;Merola A;Romagnolo A;Montanaro E;Palermo S;Lopiano L.
2019-01-01
Abstract
Weight loss (WL) is a frequent yet under-recognized complication of levodopa/carbidopa intestinal gel (LCIG) infusion, as well as a milestone of Parkinson disease (PD) disability progression. The complex association between weight loss, poor nutritional status, motor complications, and PD progression, however, remains unclear.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Fabbri_et_al-2018-European_Journal_of_Neurology.pdf
Open Access dal 23/10/2019
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
294.54 kB
Formato
Adobe PDF
|
294.54 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
